Dysregulated iron, associated with conditions like infections and cancer, promotes the development of purpose-designed chelators and hepcidin agonists as potential therapies, with a focus on cancer cells through iron-driven reactive oxygen species generation with ferroptosis, providing a novel therapeutic avenue [28]. Here, HAMP is linked to cancer.